The unique sensitivity of cHL to PD-1 blockade therapies is in part explained by the tumor intrinsic genomic alterations of the malignant cells of cHL that overexpress PD-L1 and PD-L2 ligands which, by engaging with PD-1 molecules on T-cells, drive their exhaustion [70,71]. Here, PDCD1 is linked to neoplasm.